NYSE EQUITIES INVESTIGATING REPORTED TECHNICAL ISSUE

Multiple stocks listed on the NYSE such as Berkshire Hathaway and Barrick Gold were halted

PRTA Sep 2024 22.500 put

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

4.2000

0.0000

(0.00%)

As of 02:11PM EDT. Market open.

Loading interactive chart...

Zacks
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Business Wire
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
Simply Wall St.
News Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) Forecasts
Celebrations may be in order for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...